The drug treatment research of gastrointestinal cancer in China

Eur J Surg Oncol. 2020 Oct;46(10 Pt B):e3-e6. doi: 10.1016/j.ejso.2020.06.004. Epub 2020 Jun 14.

Abstract

Gastrointestinal cancer is one of the most common cancers in China. Due to the late detection for most patients, the overall prognosis of gastrointestinal cancer is still poor. At present, the treatment of gastrointestinal cancer includes surgery, radiotherapy, ablation, chemotherapy, targeting, immunity and other treatment methods. Therefore, with the continuous improvement of individualized treatment, we hope to improve the effect of gastrointestinal cancer treatment by promoting the research progress of anti-tumor drugs. Although China's research in the field of gastrointestinal cancer drug treatment has only begun relatively recently, there has been rapid development in our progress. An increasing number of research studies led by Chinese researchers have attracted international attention, influencing clinical practices all over the world and adding to China's contribution to the global field of medicine. This article reviews China's main contributions in the clinical research of gastrointestinal cancer drugs in the past two years.

Keywords: China; Drug treatment research; Gastrointestinal cancer.

Publication types

  • Review

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Antineoplastic Agents, Immunological / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Biomedical Research
  • China
  • Colorectal Neoplasms / drug therapy*
  • ErbB Receptors / antagonists & inhibitors
  • Gastrointestinal Neoplasms / drug therapy
  • Humans
  • Immune Checkpoint Inhibitors / therapeutic use*
  • Molecular Targeted Therapy
  • Receptor, ErbB-2 / antagonists & inhibitors
  • Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors
  • Stomach Neoplasms / drug therapy*

Substances

  • Antineoplastic Agents, Immunological
  • Immune Checkpoint Inhibitors
  • ErbB Receptors
  • Receptor, ErbB-2
  • Receptors, Vascular Endothelial Growth Factor